GlassScriptPhysician profile
Michelle Leyland
NPI 1184179673
$816.59
in general payments reported to CMS, 2019-2025
23 companies · $286 in 2025
The $286 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $35.62 · 2022: $51.12 · 2023: $192 · 2024: $252 · 2025: $286.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $730.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $729.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $104.79 | 2021-2024 | Freestyle Libre 3 |
| Novo Nordisk INC | $93.68 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $55.75 | 2023-2025 | Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $54.33 | 2024-2025 | |
| Exact Sciences Corporation | $48.93 | 2024-2025 | Cologuard Collection Kit |
| Abbvie INC. | $44.78 | 2023-2025 | |
| Pfizer INC. | $40.03 | 2023 | |
| Vertex Pharmaceuticals Incorporated | $37.87 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.13 | 2024 | Jardiance |
| Phathom Pharmaceuticals, INC. | $32.84 | 2024 | Voquezna |
| Verity Pharmaceuticals INC. | $30.04 | 2025 | Tlando |
| Alkermes, INC. | $29.56 | 2024 | Vivitrol |
| Axsome Therapeutics, INC. | $25.89 | 2023 | Auvelity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.97 | 2025 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $20.17 | 2025 | Farxiga |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $19.66 | 2024 | |
| Astellas Pharma US INC | $19.54 | 2025 | Veozah |
| Dexcom, INC. | $19.38 | 2024 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $18.70 | 2023 | Xarelto |
| Lilly USA, LLC | $17.00 | 2025 | Jardiance |
| Exeltis, USA INC. | $15.00 | 2025 | Slynd |
| Merck Sharp & Dohme LLC | $14.85 | 2025 | Verquvo |
| Ironwood Pharmaceuticals, INC | $12.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Leyland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.